Newsfeeds - Spark Newswire

3 minute read

FDA
News

Corvus Pharmaceuticals Says New Preclinical Data Highlights Potential For CPI-818 As Therapy For Acute Graft Versus Host Disease In Patients Receiving Bone Marrow Transplantation

Today, 10:38 PM

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating the potential of CPI-818, the company's ITK inhibitor, for the prevention and

CRVS

1 minute read

Jefferies Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $8

By Benzinga Newsdesk

Today, 10:38 PM

Jefferies analyst Roger Song initiates coverage on Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy rating and announces Price Target of $8.

CRVS

6 minute read

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance

By Shanthi Rexaline

Today, 10:38 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ACIU

1 minute read

Corvus Pharmaceuticals Q3 EPS $(0.24) Up From $(0.33) YoY

By Benzinga Newsdesk

Today, 10:38 PM

Corvus Pharmaceuticals (NASDAQ:CRVS) reported quarterly losses of $(0.24) per share. This is a 27.27 percent increase over losses of $(0.33) per share from the same period last year.

CRVS

4 minute read

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug

By Shanthi Rexaline

Today, 10:38 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ALDX

4 minute read

51 Biggest Movers From Yesterday

By Lisa Levin

Today, 10:38 PM

Gainers Superior Drilling Products, Inc. (NYSE: SDPI) shares rose 60.6% to close at $1.75 on Thursday after jumping over 23% on Wednesday. The company, last month, reported Q2 earnings of $0.00 per share on sales of $3.40 million.

ACHL